1
|
Hunt PJ, Mehta J, Ehrenburg MR, Reyes-Capó DP, Chen C, Zieske A, Zu Y, Chévez-Barrios P, Yen MT, Pflugfelder SC. Orbital Richter Transformation With Subsequent Orbital MALT-type Lymphoma in a Patient With Chronic Lymphocytic Leukemia. Ophthalmic Plast Reconstr Surg 2024; 40:e205-e209. [PMID: 39136940 DOI: 10.1097/iop.0000000000002719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2024]
Abstract
A 74-year-old man with a history of chronic lymphocytic leukemia (CLL) presented with large salmon-colored patch lesions along the inferior fornix and superotemporal conjunctiva of the OS. The patient underwent an incisional biopsy of the lesions, which showed a CLL with areas of large B-cell lymphoma, consistent with Richter transformation. Following medical and radiation-based therapy of these lesions, the patient returned 3 months later with inferomedial preseptal swelling in the contralateral eye, which biopsy proved to be recurrent/resistant low-grade CLL with a posttreatment extranodal marginal zone B-cell lymphoma pattern. This case exemplifies a rare presentation of CLL with Richter transformation and a recurrent/resistant posttreatment orbital CLL with a marginal zone B-cell lymphoma-like pattern.
Collapse
MESH Headings
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Aged
- Male
- Lymphoma, B-Cell, Marginal Zone/diagnosis
- Lymphoma, B-Cell, Marginal Zone/pathology
- Lymphoma, B-Cell, Marginal Zone/radiotherapy
- Orbital Neoplasms/diagnosis
- Orbital Neoplasms/pathology
- Biopsy
- Cell Transformation, Neoplastic/pathology
Collapse
Affiliation(s)
- Patrick J Hunt
- Department of Ophthalmology, Baylor College of Medicine
- Medical Scientist Training Program, Department of Ophthalmology, Baylor College of Medicine
| | - Jeel Mehta
- Department of Ophthalmology, Baylor College of Medicine
| | - Matthew R Ehrenburg
- Department of Ophthalmology, Baylor College of Medicine
- Medical Scientist Training Program, Department of Ophthalmology, Baylor College of Medicine
| | | | - Chen Chen
- Department of Pathology, Baylor College of Medicine
- Department of Pathology & Genomic Medicine, Houston Methodist Medical Center, Houston, Texas, U.S.A
| | - Arthur Zieske
- Department of Pathology & Genomic Medicine, Houston Methodist Medical Center, Houston, Texas, U.S.A
| | - Yuli Zu
- Department of Pathology & Genomic Medicine, Houston Methodist Medical Center, Houston, Texas, U.S.A
| | - Patricia Chévez-Barrios
- Department of Ophthalmology, Baylor College of Medicine
- Department of Pathology & Genomic Medicine, Houston Methodist Medical Center, Houston, Texas, U.S.A
| | - Michael T Yen
- Department of Ophthalmology, Baylor College of Medicine
| | | |
Collapse
|
2
|
Märklin M, Fuchs AR, Tandler C, Heitmann JS, Salih HR, Kauer J, Quintanilla-Martinez L, Wirths S, Kopp HG, Müller MR. Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia. Front Immunol 2020; 11:1995. [PMID: 32983140 PMCID: PMC7492521 DOI: 10.3389/fimmu.2020.01995] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 07/23/2020] [Indexed: 11/17/2022] Open
Abstract
Most patients with chronic lymphocytic leukemia (CLL) exhibit an indolent disease course and unresponsive B cell receptors (BCRs) exemplified by an anergic phenotype of their leukemic cells. In up to 5% of patients, CLL transforms from an indolent subtype to an aggressive form of B cell lymphoma (Richter's syndrome), which is associated with worse disease outcome and severe downregulation of NFAT2. Here we show that ablation of the tyrosine kinase LCK, which has previously been characterized as a main NFAT2 target gene in CLL, leads to loss of the anergic phenotype, thereby restoring BCR signaling, which results in an acceleration of CLL. Our study identifies LCK as a main player in mediating BCR unresponsiveness and its role as a crucial regulator of anergy in CLL.
Collapse
Affiliation(s)
- Melanie Märklin
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.,Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany
| | - Alexander R Fuchs
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany
| | - Claudia Tandler
- Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany
| | - Jonas S Heitmann
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.,Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany
| | - Helmut R Salih
- Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany
| | - Joseph Kauer
- Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany
| | | | - Stefan Wirths
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany
| | - Hans-Georg Kopp
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.,Department of Molecular Oncology and Thoracic Oncology, Robert-Bosch-Hospital Stuttgart, Stuttgart, Germany
| | - Martin R Müller
- Department of Hematology, Oncology and Clinical Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.,Department of Hematology, Oncology and Immunology, Klinikum Region Hannover, KRH Klinikum Siloah, Hanover, Germany
| |
Collapse
|
3
|
Zheng XQ, Zhu HY, Ding CY, Wang L, Fan L, Xu W, Li JY. [Clinical value of PET/CT in the diagnosis of Richter syndrome]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2020; 41:689-693. [PMID: 32942827 PMCID: PMC7525174 DOI: 10.3760/cma.j.issn.0253-2727.2020.08.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Indexed: 12/05/2022]
Affiliation(s)
- X Q Zheng
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - H Y Zhu
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 210031, China
| | - C Y Ding
- Department of Nuclear Medicine, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - L Wang
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - L Fan
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - W Xu
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - J Y Li
- Department of Hematology, Key Laboratory of Hematology of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing 210031, China
| |
Collapse
|
4
|
Kawase K, Naiki T, Naiki-Ito A, Yanada M, Ikegami Y, Ota Y, Hattori T, Matsuyama N, Hamakawa T, Maruyama T, Yasui T. Rare case of Richter syndrome with testicular involvement successfully obtained good prognosis with rapid operation and immunochemotherapy. IJU Case Rep 2019; 2:232-235. [PMID: 32743423 PMCID: PMC7292090 DOI: 10.1002/iju5.12096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Accepted: 05/20/2019] [Indexed: 12/02/2022] Open
Abstract
Introduction Richter syndrome refers to the transformation from chronic lymphocytic leukemia to assaultive lymphoma, often a diffuse large B‐cell lymphoma, and has a greatly poor prognosis. Richter syndrome is characterized by rapidly growing lymphadenopathy but rarely presents with extra‐nodal involvement, common sites being the digestive tract, lungs, kidneys, and central nervous system. However, Richter syndrome with testicular involvement is extremely rare. Case presentation Herein we report a very scare case of a male at the age of 72 with Richter syndrome and testicular involvement, diagnosed by the investigation of bilateral scrotal swellings. The patient had attained disease‐free survival for over a year with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and the intrathecal administration of chemotherapeutic agents after diagnosis by immediate orchiectomy. Conclusion An early pathological diagnosis by immediate orchiectomy and the early initiation of induction immunochemotherapy may be good prognostic factors in Richter syndrome involving the testes.
Collapse
Affiliation(s)
- Kengo Kawase
- Department of Nephro-Urology Graduate School of Medical Sciences Nagoya City University Nagoya Aichi Japan.,Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Taku Naiki
- Department of Nephro-Urology Graduate School of Medical Sciences Nagoya City University Nagoya Aichi Japan
| | - Aya Naiki-Ito
- Pathology Division Nagoya City East Medical Center Nagoya Aichi Japan
| | - Masamitsu Yanada
- Department of Hematology and Cell Therapy Aichi Cancer Center Nagoya Aichi Japan
| | - Yosuke Ikegami
- Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Yuya Ota
- Department of Nephro-Urology Graduate School of Medical Sciences Nagoya City University Nagoya Aichi Japan.,Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Tatsuya Hattori
- Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Nayuka Matsuyama
- Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Takashi Hamakawa
- Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Tetsuji Maruyama
- Department of Urology Nagoya City East Medical Center Nagoya Aichi Japan
| | - Takahiro Yasui
- Department of Nephro-Urology Graduate School of Medical Sciences Nagoya City University Nagoya Aichi Japan
| |
Collapse
|
5
|
Karousi P, Katsaraki K, Papageorgiou SG, Pappa V, Scorilas A, Kontos CK. Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. Hematol Oncol 2019; 37:498-504. [PMID: 30945323 DOI: 10.1002/hon.2616] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Accepted: 04/01/2019] [Indexed: 12/21/2022]
Affiliation(s)
- Paraskevi Karousi
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece
| | - Katerina Katsaraki
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece
| | - Sotirios G Papageorgiou
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", Athens, Greece
| | - Vasiliki Pappa
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", Athens, Greece
| | - Andreas Scorilas
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece
| | - Christos K Kontos
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
6
|
Müller DJ, Wirths S, Fuchs AR, Märklin M, Heitmann JS, Sturm M, Haap M, Kirschniak A, Sasaki Y, Kanz L, Kopp HG, Müller MR. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. J Leukoc Biol 2018; 105:531-538. [PMID: 30556925 DOI: 10.1002/jlb.2ab0218-076rr] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Revised: 11/20/2018] [Accepted: 11/27/2018] [Indexed: 12/29/2022] Open
Abstract
Chronic lymphocytic leukemia (CLL) can be defined as a clonal expansion of B cells with stereotypic BCRs. Somatic hypermutation of the BCR heavy chains (IGVH) defines a subgroup of patients with a better prognosis. In up to 10% of CLL cases, a transformation to an aggressive B cell lymphoma (Richter's syndrome) with a dismal prognosis can be observed over time. NFAT proteins are transcription factors originally identified in T cells, which also play an important role in B cells. The TCL1 transgenic mouse is a well-accepted model of CLL. Upon B cell-specific deletion of NFAT2, TCL1 transgenic mice develop a disease resembling human Richter's syndrome. Whereas TCL1 B cells exhibit tonic anergic BCR signaling characteristic of human CLL, loss of NFAT2 expression leads to readily activated BCRs indicating different BCR usage with altered downstream signaling. Here, we analyzed BCR usage in wild-type and TCL1 transgenic mice with and without NFAT2 deletion employing conventional molecular biology techniques and next-generation sequencing (NGS). We demonstrate that the loss of NFAT2 in CLL precipitates the selection of unmutated BCRs and the preferential usage of certain VDJ recombinations, which subsequently results in the accelerated development of oligoclonal disease.
Collapse
Affiliation(s)
- David J Müller
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Stefan Wirths
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Alexander R Fuchs
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Melanie Märklin
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Jonas S Heitmann
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Marc Sturm
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
| | - Michael Haap
- Department of Endocrinology, Diabetology, Clinical Pathology and Metabolism, University of Tübingen, Tübingen, Germany
| | | | - Yoshiteru Sasaki
- Department of Hematology and Oncology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan
| | - Lothar Kanz
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Hans-Georg Kopp
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| | - Martin R Müller
- Department of Oncology, Hematology and Immunology, University of Tübingen, Tübingen, Germany
| |
Collapse
|
7
|
Papageorgiou SG, Diamantopoulos MA, Kontos CK, Bouchla A, Vasilatou D, Bazani E, Scorilas A, Pappa V. MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. Leuk Lymphoma 2018; 60:658-667. [PMID: 29911923 DOI: 10.1080/10428194.2018.1461861] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
MicroRNA-92a-3p (miR-92a-3p) derives from the oncogenic miR-17/92 cluster and its highly homologous miR-106a/363 cluster. miR-92a-3p regulates the expression of key transcription factors such as HIF1 and inhibits SOCS1 to enhance the anti-apoptotic STAT3/IL6 signaling pathway. In this study, we assessed the putative usefulness of miR-92a-3p as a prognostic and/or diagnostic biomarker in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was extracted from mononuclear cells isolated from the peripheral blood of 88 CLL patients and 36 non-leukemic blood donors, was polyadenylated and reversely transcribed. miR-92a-3p expression was quantified using an accurate qPCR method. miR-92a-3p levels were significantly lower in peripheral blood mononuclear cells of CLL patients. Overall survival (OS) analysis revealed that high miR-92a-3p expression predicts significantly prolonged OS of CLL patients. Interestingly, miR-92a-3p overexpression remains a significant prognosticator in subgroups of CLL patients with distinct prognosis. In conclusion, miR-92a-3p overexpression is a potential surrogate biomarker of favorable outcome of CLL patients.
Collapse
Affiliation(s)
- Sotirios G Papageorgiou
- a Second Department of Internal Medicine and Research Unit , University General Hospital "Attikon" , Athens , Greece
| | - Marios A Diamantopoulos
- b Department of Biochemistry and Molecular Biology , National and Kapodistrian University of Athens , Athens , Greece
| | - Christos K Kontos
- b Department of Biochemistry and Molecular Biology , National and Kapodistrian University of Athens , Athens , Greece
| | - Anthi Bouchla
- a Second Department of Internal Medicine and Research Unit , University General Hospital "Attikon" , Athens , Greece
| | - Diamantina Vasilatou
- a Second Department of Internal Medicine and Research Unit , University General Hospital "Attikon" , Athens , Greece
| | - Efthymia Bazani
- a Second Department of Internal Medicine and Research Unit , University General Hospital "Attikon" , Athens , Greece
| | - Andreas Scorilas
- b Department of Biochemistry and Molecular Biology , National and Kapodistrian University of Athens , Athens , Greece
| | - Vasiliki Pappa
- a Second Department of Internal Medicine and Research Unit , University General Hospital "Attikon" , Athens , Greece
| |
Collapse
|
8
|
Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. Leuk Res 2018; 70:1-7. [PMID: 29715621 DOI: 10.1016/j.leukres.2018.04.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Revised: 04/25/2018] [Accepted: 04/25/2018] [Indexed: 12/21/2022]
Abstract
MicroRNA-20b-5p (miR-20b-5p) is part of the miR-106a/363 cluster and a member of the cancer-related miR-17 family. miR-20b-5p regulates important transcription factors, including hypoxia-inducible factor 1 (HIF1) and signal transducer and activator of transcription 3 (STAT3). Recently, the dysregulation of miR-20b-5p expression has been observed in many B-cell lymphomas and T-cell leukemias. In this research study, we examined the putative prognostic value of miR-20b-5p in CLL. Therefore, total RNA was isolated from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients; next, total RNA was polyadenylated and first-strand cDNA was synthesized, using an oligo-dT-adapter primer. miR-20b-5p expression was quantified using an in-house-developed real-time quantitative PCR assay. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-20b-5p expression predicts better OS for CLL patients (p < 0.001). Interestingly, miR-20b-5p overexpression retains its favorable prognostic role in CLL patients of intermediate risk or stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable (IGHV) region]. In conclusion, miR-20b-5p is a potential independent molecular biomarker of favorable prognosis in CLL.
Collapse
|
9
|
Papageorgiou SG, Kontos CK, Diamantopoulos MA, Bouchla A, Glezou E, Bazani E, Pappa V, Scorilas A. MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. DISEASE MARKERS 2017; 2017:2046545. [PMID: 29463948 PMCID: PMC5804407 DOI: 10.1155/2017/2046545] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 11/20/2017] [Indexed: 12/28/2022]
Abstract
MicroRNA-155-5p (miR-155-5p) is a proinflammatory, oncogenic miRNA, involved in various physiological processes, including hematopoiesis, immunity, inflammation, and cell lineage differentiation. It regulates important transcription factors, such as E2F2, hypoxia-inducible factor 1 (HIF1), and FOXO3. Recently, the dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis. In this research study, we investigated the potential diagnostic and prognostic value of miR-155-5p in CLL. To achieve our goal, we isolated total RNA from peripheral blood mononuclear cells (PBMCs) collected from 88 CLL patients and 36 nonleukemic blood donors and performed polyadenylation of total RNA and reverse transcription. Next, we quantified miR-155-5p levels using an in-house-developed real-time quantitative PCR method, before proceeding to extensive biostatistical analysis. Thus, it appears that miR-155-5p is significantly overexpressed in PBMCs of CLL patients and can distinguish them from nonleukemic population. Kaplan-Meier OS analysis and bootstrap univariate Cox regression showed that high miR-155-5p expression predicts inferior OS for CLL patients (p < 0.001). Interestingly, miR-155-5p overexpression retains its unfavorable prognostic role in CLL patients stratified according to established prognostic factors [CD38 expression and mutational status of the immunoglobulin heavy chain variable region (IGHV)]. Thus, miR-155-5p appears as a promising, independent molecular biomarker of unfavorable prognosis in CLL.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Cell Line, Tumor
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/blood
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Male
- MicroRNAs/blood
- MicroRNAs/genetics
- Middle Aged
- Prognosis
- Survival Analysis
- Up-Regulation
Collapse
Affiliation(s)
- Sotirios G. Papageorgiou
- Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Christos K. Kontos
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | - Marios A. Diamantopoulos
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | - Anthi Bouchla
- Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Eirini Glezou
- Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Efthymia Bazani
- Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Vasiliki Pappa
- Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Andreas Scorilas
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| |
Collapse
|
10
|
Märklin M, Heitmann JS, Fuchs AR, Truckenmüller FM, Gutknecht M, Bugl S, Saur SJ, Lazarus J, Kohlhofer U, Quintanilla-Martinez L, Rammensee HG, Salih HR, Kopp HG, Haap M, Kirschniak A, Kanz L, Rao A, Wirths S, Müller MR. NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. Nat Commun 2017; 8:755. [PMID: 28970470 PMCID: PMC5624906 DOI: 10.1038/s41467-017-00830-y] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Accepted: 07/31/2017] [Indexed: 11/18/2022] Open
Abstract
Chronic lymphocytic leukaemia (CLL) is a clonal disorder of mature B cells. Most patients are characterised by an indolent disease course and an anergic phenotype of their leukaemia cells, which refers to a state of unresponsiveness to B cell receptor stimulation. Up to 10% of CLL patients transform from an indolent subtype to an aggressive form of B cell lymphoma over time (Richter´s syndrome) and show a significantly worse treatment outcome. Here we show that B cell-specific ablation of Nfat2 leads to the loss of the anergic phenotype culminating in a significantly compromised life expectancy and transformation to aggressive disease. We further define a gene expression signature of anergic CLL cells consisting of several NFAT2-dependent genes including Cbl-b, Grail, Egr2 and Lck. In summary, this study identifies NFAT2 as a crucial regulator of the anergic phenotype in CLL.NFAT2 is a transcription factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL manifestation are still unclear. Here the authors show, by analysing mouse CLL models and characterising biopsies from CLL patients, that NFAT2 is an important regulator for the anergic phenotype of CLL.
Collapse
Affiliation(s)
- Melanie Märklin
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Jonas S Heitmann
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Alexander R Fuchs
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Felicia M Truckenmüller
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Michael Gutknecht
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Stefanie Bugl
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Sebastian J Saur
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Juliane Lazarus
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Ursula Kohlhofer
- Department of Pathology, University of Tübingen, Tübingen, 72076, Germany
| | | | | | - Helmut R Salih
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
- Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
| | - Hans-Georg Kopp
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Michael Haap
- Department of Endocrinology, Diabetology, Clinical Pathology and Metabolism, University of Tübingen, Tübingen, 72076, Germany
| | | | - Lothar Kanz
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Anjana Rao
- La Jolla Institute of Allergy and Immunology, La Jolla, CA, 92037, USA
| | - Stefan Wirths
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany
| | - Martin R Müller
- Department of Oncology, Haematology and Immunology, University of Tübingen, Tübingen, 72076, Germany.
| |
Collapse
|
11
|
Kontos CK, Papageorgiou SG, Diamantopoulos MA, Scorilas A, Bazani E, Vasilatou D, Gkontopoulos K, Glezou E, Stavroulaki G, Dimitriadis G, Pappa V. mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. Leuk Res 2016; 53:65-73. [PMID: 28038356 DOI: 10.1016/j.leukres.2016.11.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 11/24/2016] [Accepted: 11/28/2016] [Indexed: 12/17/2022]
Abstract
The hypoxia inducible factor 1 (HIF1) is a heterodimeric transcription factor that ultimately regulates cellular responses to changes in oxygen tension. In this study, we examined the potential diagnostic and prognostic potential of the mRNA expression of HIF1 regulatory α-subunit (HIF1A) in chronic lymphocytic leukemia (CLL). For this purpose, total RNA was isolated from peripheral blood mononuclear cells collected from 88 CLL patients and 33 non-leukemic blood donors, and poly(A)-RNA was reversely transcribed. HIF1A mRNA levels were quantified using real-time PCR. Kaplan-Meier survival analysis showed that high HIF1A mRNA expression predicts inferior overall survival for CLL patients (p=0.001). Bootstrap univariate Cox regression analysis confirmed that HIF1A mRNA overexpression is a significant unfavorable prognosticator in CLL (hazard ratio=3.75, bias-corrected and accelerated 95% confidence interval=1.43-24.36, bootstrap p<0.001), independent of other established prognostic factors, including CD38 expression, the mutational status of the immunoglobulin heavy chain variable region (IGHV), and the clinical stage (Binet or Rai stage) or risk group (p<0.001 in all cases). Interestingly, HIF1A mRNA positivity retains its unfavorable prognostic value in distinct subgroups of patients, stratified according to established prognostic factors. Thus, HIF1A mRNA overexpression can be regarded as a promising, independent molecular biomarker of unfavorable prognosis in CLL.
Collapse
Affiliation(s)
- Christos K Kontos
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece; Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | - Sotirios G Papageorgiou
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Marios A Diamantopoulos
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | - Andreas Scorilas
- Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece
| | - Efthimia Bazani
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Diamantina Vasilatou
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Konstantinos Gkontopoulos
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Eirini Glezou
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Georgia Stavroulaki
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - George Dimitriadis
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece
| | - Vasiliki Pappa
- Second Department of Internal Medicine and Research Unit, University General Hospital "Attikon", 1 Rimini St., Haidari, 12462 Athens, Greece.
| |
Collapse
|
12
|
Kontos CK, Adamopoulos PG, Papageorgiou SG, Pappa V, Scorilas A. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. Clin Chem Lab Med 2016; 54:315-24. [PMID: 26351937 DOI: 10.1515/cclm-2015-0456] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 06/24/2015] [Indexed: 11/15/2022]
Abstract
BACKGROUND Tissue kallikrein and kallikrein-related peptidases (KLKs) compose a family of serine endopeptidases with much clinical interest in oncology, as their potential as diagnostic and/or prognostic molecular biomarkers in several human malignancies has already been evidenced. However, none of the members of this family has ever been studied in hematological malignancies. Based on our preliminary results regarding the differential mRNA expression of several KLK genes in peripheral blood mononuclear cells (PBMCs) of patients with chronic lymphocytic leukemia (CLL) compared to healthy blood donors, we decided to study the diagnostic and prognostic potential of KLK14 mRNA expression in CLL. METHODS Total RNA was isolated from 69 CLL patients and 31 non-leukemic blood donors. After reverse transcription of poly(A)-RNA, KLK14 mRNA levels were quantified using a sensitive and accurate quantitative real-time PCR (qPCR) methodology. RESULTS According to ROC analysis, KLK14 mRNA overexpression successfully discriminated CLL patients from normal population (area under the curve [AUC] 0.89, 95% confidence interval [CI] 0.83-0.95, p<0.001). Moreover, although not clearly related to clinical staging or other prognostic factors including IGHV mutational status and CD38 expression, strong KLK14 mRNA expression was shown to predict reduced overall survival of CLL patients (p=0.026) using Kaplan-Meier survival analysis. The unfavorable prognostic value of KLK14 mRNA overexpression in CLL patients' PBMCs was independent of established prognostic factors of the disease, as shown by multivariate Cox regression analysis (hazard ratio [HR] 14.65, 95% CI 1.81-118.36, p=0.012). CONCLUSIONS KLK14 mRNA expression merits further investigation as a potential prognostic biomarker of overall survival of patients with CLL.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Area Under Curve
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Complementarity Determining Regions/genetics
- Disease-Free Survival
- Female
- Gene Rearrangement
- Humans
- Immunophenotyping
- Kallikreins/genetics
- Kaplan-Meier Estimate
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukocytes, Mononuclear/metabolism
- Male
- Middle Aged
- Mutation
- Prognosis
- Proportional Hazards Models
- RNA, Messenger/metabolism
- ROC Curve
- Real-Time Polymerase Chain Reaction
Collapse
|
13
|
A Rare Cause of Cavitary Lesion in the Lung: Richter's Transformation. Case Rep Pulmonol 2015; 2015:945268. [PMID: 25810941 PMCID: PMC4354960 DOI: 10.1155/2015/945268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Revised: 02/17/2015] [Accepted: 02/21/2015] [Indexed: 11/26/2022] Open
Abstract
Richter's transformation (RT) refers to the development of aggressive lymphoma during the course of CLL. Clinically, patients with RT present with an aggressive disease course with rapidly enlarging lymph nodes, hepatosplenomegaly, and elevated serum lactate dehydrogenase levels. But rarely it presents with extra nodal organ involvement at the beginning. Common sites of extra nodal involvement are the gastrointestinal tract, eye, central nervous system, lung, and kidney. We are reporting this case that was presented with RT in the lung involvement diagnosed while researching cavitary lesion etiology.
Collapse
|
14
|
The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy. Crit Rev Oncol Hematol 2015; 94:149-63. [PMID: 25604499 DOI: 10.1016/j.critrevonc.2014.12.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 11/11/2014] [Accepted: 12/22/2014] [Indexed: 12/25/2022] Open
Abstract
Nearly all cancers are linked by the inexorable phenotype of metastasis as malignant growths have the capability to spread from their place of origin to distant sites throughout the body. While different cancers may have various propensities to migrate towards specific locations, they are all linked by this unifying principal. Unlike most neoplasms, leukaemia has inherent cell motility as leukocytes are required to move throughout the vascular system, suggesting that no mutations are required for anchorage independent growth. As such, it seems likely that leukaemias are inherently metastatic, endowed with the deadliest phenotype of cancer simply due to cell of origin. This article presents the biology of metastasis development and how leukaemia cells are inherently provided these phenotypic characteristics. It is then proposed how clinicians may be able to exploit the motility of leukaemia and metastatic emboli of other cancer types through an approach known as sonodynamic therapy (SDT), a treatment modality that combines chemotherapeutic agents with ultrasound to preferentially damage malignant cells. As experimental evidence has indicated, SDT is a promising therapeutic approach in need of clinical testing for further validation.
Collapse
|
15
|
Spontaneous retroperitoneal hemorrhage in a patient with prolymphocytic transformation of chronic lymphocytic leukemia. Case Rep Hematol 2013; 2013:802376. [PMID: 24024050 PMCID: PMC3760287 DOI: 10.1155/2013/802376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Accepted: 07/18/2013] [Indexed: 11/20/2022] Open
Abstract
Prolymphocytic transformation of chronic lymphocytic leukemia is a rare but recognized entity. We present the case of a 76-year-old gentleman with a previous diagnosis of chronic lymphocytic leukemia who presented with fatigue, fever, and a white blood cell count of 500 000 with prolymphocytes on peripheral blood examination. Chlorambucil and dexamethasone were initiated. He developed progressive anemia during his admission with no clear cause on initial CT examination. Bilateral hip pain began several days later and he was unfortunately diagnosed with a large spontaneous retroperitoneal hemorrhage postmortem. This condition is rare and generally occurs in those receiving therapeutic anticoagulation or dialysis, with known bleeding disorders or vascular malformation, none of which were present in our patient. Pathology revealed marked leukemoid engorgement of the vessels of many organs with prolymphocytes. We discuss the potential etiologies and relationships between these critical diagnoses.
Collapse
|
16
|
Lu Y, Huang Q. A unique lethal blastoid transformation of B-cell chronic lymphocytic leukemia carrying ATM/11q deletion and trisomy 12. Leuk Res 2009; 33:e124-6. [DOI: 10.1016/j.leukres.2009.02.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2009] [Revised: 01/31/2009] [Accepted: 02/05/2009] [Indexed: 11/27/2022]
|
17
|
Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008; 142:709-16. [DOI: 10.1111/j.1365-2141.2008.07248.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|